DK3352734T3 - Behandling af alopecia areata - Google Patents

Behandling af alopecia areata Download PDF

Info

Publication number
DK3352734T3
DK3352734T3 DK16775134.6T DK16775134T DK3352734T3 DK 3352734 T3 DK3352734 T3 DK 3352734T3 DK 16775134 T DK16775134 T DK 16775134T DK 3352734 T3 DK3352734 T3 DK 3352734T3
Authority
DK
Denmark
Prior art keywords
treatment
alopecia areata
areata
alopecia
Prior art date
Application number
DK16775134.6T
Other languages
Danish (da)
English (en)
Inventor
Michael Sierra
Tord Labuda
Atsuo Tanimoto
Yuichi Shinozaki
Original Assignee
Japan Tobacco Inc
Leo Pharma As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from JP2015190849A external-priority patent/JP2017066061A/ja
Application filed by Japan Tobacco Inc, Leo Pharma As filed Critical Japan Tobacco Inc
Application granted granted Critical
Publication of DK3352734T3 publication Critical patent/DK3352734T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
DK16775134.6T 2015-09-24 2016-09-22 Behandling af alopecia areata DK3352734T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP15186644 2015-09-24
JP2015190849A JP2017066061A (ja) 2015-09-29 2015-09-29 円形脱毛症治療剤
PCT/EP2016/072531 WO2017050891A1 (en) 2015-09-24 2016-09-22 Treatment of alopecia areata

Publications (1)

Publication Number Publication Date
DK3352734T3 true DK3352734T3 (da) 2020-03-30

Family

ID=57047187

Family Applications (1)

Application Number Title Priority Date Filing Date
DK16775134.6T DK3352734T3 (da) 2015-09-24 2016-09-22 Behandling af alopecia areata

Country Status (27)

Country Link
US (3) US20180263986A1 (enExample)
EP (1) EP3352734B1 (enExample)
JP (1) JP6776345B2 (enExample)
KR (1) KR102728341B1 (enExample)
CN (1) CN108135834B (enExample)
AU (3) AU2016325388A1 (enExample)
BR (1) BR112018005771B1 (enExample)
CA (1) CA2998972A1 (enExample)
CY (1) CY1122837T1 (enExample)
DK (1) DK3352734T3 (enExample)
ES (1) ES2779762T3 (enExample)
HR (1) HRP20200472T1 (enExample)
HU (1) HUE049052T2 (enExample)
IL (3) IL312861A (enExample)
LT (1) LT3352734T (enExample)
MX (1) MX375024B (enExample)
MY (1) MY196541A (enExample)
PL (1) PL3352734T3 (enExample)
PT (1) PT3352734T (enExample)
RS (1) RS60365B1 (enExample)
RU (1) RU2754997C2 (enExample)
SG (1) SG10202111361TA (enExample)
SI (1) SI3352734T1 (enExample)
TW (1) TWI720022B (enExample)
UA (1) UA124192C2 (enExample)
WO (1) WO2017050891A1 (enExample)
ZA (1) ZA201801722B (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN119367282A (zh) * 2019-12-27 2025-01-28 乐敦制药株式会社 水性组合物
WO2023029943A1 (zh) * 2021-09-03 2023-03-09 星药科技(北京)有限公司 一种芳杂环化合物及其制备方法和用途
JP2025514747A (ja) 2022-04-20 2025-05-09 レオ ファーマ アクティーゼルスカブ 前頭部線維性脱毛症の治療

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI466885B (zh) * 2009-07-31 2015-01-01 Japan Tobacco Inc 含氮螺環化合物及其醫藥用途
US8637569B2 (en) * 2009-10-22 2014-01-28 Api Genesis, Llc Methods of increasing solubility of poorly soluble compounds and methods of making and using formulations of such compounds
US20140343034A1 (en) * 2013-04-25 2014-11-20 Japan Tobacco Inc. Skin barrier function improving agent
WO2015060208A1 (ja) * 2013-10-21 2015-04-30 日本たばこ産業株式会社 眼疾患の治療剤又は予防剤

Also Published As

Publication number Publication date
JP2018528238A (ja) 2018-09-27
SG10202111361TA (en) 2021-12-30
UA124192C2 (uk) 2021-08-04
LT3352734T (lt) 2020-04-10
RS60365B1 (sr) 2020-07-31
ZA201801722B (en) 2025-06-25
AU2016325388A1 (en) 2018-03-29
EP3352734B1 (en) 2020-01-15
NZ740690A (en) 2024-11-29
ES2779762T3 (es) 2020-08-19
RU2754997C2 (ru) 2021-09-08
EP3352734A1 (en) 2018-08-01
IL298520A (en) 2023-01-01
SI3352734T1 (sl) 2020-07-31
BR112018005771B1 (pt) 2023-12-05
HUE049052T2 (hu) 2020-09-28
MY196541A (en) 2023-04-19
CA2998972A1 (en) 2017-03-30
CN108135834A (zh) 2018-06-08
US20180263986A1 (en) 2018-09-20
KR20180054767A (ko) 2018-05-24
IL312861A (en) 2024-07-01
AU2024204716B2 (en) 2026-06-11
AU2022202508A1 (en) 2022-05-12
HRP20200472T1 (hr) 2020-09-18
JP6776345B2 (ja) 2020-10-28
US20240398809A1 (en) 2024-12-05
RU2018114922A (ru) 2019-10-28
MX2018003332A (es) 2018-08-16
PL3352734T3 (pl) 2020-08-24
TWI720022B (zh) 2021-03-01
CN108135834B (zh) 2021-07-27
WO2017050891A1 (en) 2017-03-30
PT3352734T (pt) 2020-03-31
RU2018114922A3 (enExample) 2019-12-11
US20220088020A1 (en) 2022-03-24
BR112018005771A2 (pt) 2018-10-09
AU2024204716A1 (en) 2024-07-25
KR102728341B1 (ko) 2024-11-11
MX375024B (es) 2025-03-06
HK1257770A1 (en) 2019-10-25
TW201717955A (zh) 2017-06-01
IL257918A (en) 2018-05-31
CY1122837T1 (el) 2021-05-05

Similar Documents

Publication Publication Date Title
DK3134530T3 (da) Behandling af hyperbilirubinæmi
PL3288581T3 (pl) Sposób leczenia nowotworu
DK2968208T3 (da) Behandling af kataplexi
DK3244965T3 (da) Behandling af hovedpine med elektrisk stimulering
PL3325443T3 (pl) Sposób otrzymywania pridopidyny
DK3377516T3 (da) Sammensætning til behandling af cancer
IL272851A (en) Methods of using dipivefrin
IL257509A (en) Biomarkers for the treatment of alopecia areata
DK3506904T3 (da) Behandling af demens
DK3261726T3 (da) Sammensætning til behandling af acne
DK3458052T3 (da) Kombinationsbehandling af cancer
DK3307267T3 (da) Behandling af multipel sklerose
DK2961378T3 (da) Fremgangsmåder til behandlingen af mitochondrisk sygdom
PL3393468T3 (pl) Metody leczenia niedoboru odporności
DK3283210T3 (da) Fremgangsmåde
DK3318115T3 (da) Maskine til behandling af svinegylle
DK3418273T3 (da) Derivater af flavagliner
DK3368044T3 (da) Behandling af hepatisk steatose-relateret oligo-ovulation
IL254825A0 (en) Methods of treatment with taselisib
DK3297619T3 (da) Terapeutiske anvendelser af L-4-chlorkynurenin
DK3302573T3 (da) Sammensætning til behandlingen af hjernelæsioner
IL256186A (en) Treatment of nut midline carcinoma
IL254502B (en) Solid forms of menaquinols
PT3445167T (pt) Criopreservação de fases juvenis de perceves
EP3402328A4 (en) FISH FALL RUNNER